UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No.)

Filed by the Registrant □	
Filed by a Party other than the Registrant ⊠	
Check the appropriate box:	
	Preliminary Proxy Statement
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
	Definitive Proxy Statement
\boxtimes	Definitive Additional Materials
	Soliciting Material Under § 240.14a-12
WISDOMTREE, INC.	
(Name of Registrant as Specified In Its Charter)	
ETFS CAPITAL LIMITED	
GRAHAM TUCKWELL	
	BRUCE AUST TONIA PANKOPF
(Name of Persons(s) Filing Proxy Statement, if other than the Registrant)	
(1. min vo. 1. v.	
Payment of Filing Fee (Check all boxes that apply):	
\boxtimes	No fee required
	Fee paid previously with preliminary materials
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

ETFS Capital Limited, together with the other participants named herein (collectively, "ETFS Capital"), has filed a definitive proxy statement and accompanying GOLD proxy card with the Securities and Exchange Commission to be used to solicit votes for the election of its slate of highly-qualified director nominees at the 2023 annual meeting of stockholders (the "Annual Meeting") of WisdomTree, Inc., a Delaware corporation (the "Company").

On May 9, 2023, ETFS Capital posted the following materials to www.WiseUpWT.com:

Tonia Pankopf

- Ms Pankopf currently serves as Managing Partner of Pareto Advisors, LLC, an investment, financial and strategic advisory firm, since 2005.
- Previously, Ms. Pankopf served on the board of directors, as well as serving as Audit Chair
 and as a member of the Nominating and Corporate Governance and CEO Search
 Committees, of Landec Corporation (n/k/a Lifecore Biomedical, Inc.), a fully integrated
 contract development and manufacturing organization in the pharmaceutical industry, from
 November 2012 to November 2022.
- From 2003 to 2017, Ms. Pankopf served on the board of directors of Oxford Square Capital Corporation (formerly TICC Capital Corporation), a registered closed-end investment management company.
- Earlier in her career, Ms. Pankopf held Vice President and Senior Equity Analyst positions at Goldman Sachs & Co., a global investment bank, and Merrill Lynch & Co., a global investment bank.
- Ms. Pankopf's experience also includes hedge fund portfolio management at PA.W. Capital Partners, an investment advisory firm, and Palladio Capital Management, an investment advisory firm.
- Ms. Pankopf previously served on the Board of the University System of Maryland Foundation, from 2006 to 2012.
- Ms. Pankopf is a Governance Fellow and member of the National Association of Corporate Directors. She is also a qualified financial expert.
- Ms. Pankopf received a Bachelor of Arts summa cum laude from the University of Maryland and a Master of Science degree from the London School of Economics.

We believe that Ms. Pankopt's 28 years' of investment experience with domestic and international public and private companies, coupled with her 20 years of public company board and corporate governance experience and significant capital market and corporate finance expertise, will make her a valuable addition to the Board.



